LexAurum Advisors LLC Has $380,000 Stake in Amgen Inc. (NASDAQ:AMGN)

LexAurum Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 22.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,458 shares of the medical research company’s stock after buying an additional 264 shares during the quarter. LexAurum Advisors LLC’s holdings in Amgen were worth $380,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC bought a new position in Amgen during the 2nd quarter worth approximately $30,000. Matrix Trust Co bought a new position in Amgen in the third quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory bought a new position in Amgen in the third quarter valued at approximately $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. UBS Group cut their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Finally, Redburn Partners cut their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $314.65.

Amgen Price Performance

Shares of AMGN opened at $275.42 on Friday. The company has a market cap of $148.05 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company’s fifty day simple moving average is $271.55 and its 200 day simple moving average is $306.24. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the company earned $4.96 earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis. On average, research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is currently 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.